AI Article Synopsis

  • The study aims to evaluate how changing therapy days for haemophilia B medications could affect spending compared to 2022.
  • It analyzes data on all coagulation factor IX products used in Italy to estimate potential cost changes by switching 5% to 20% of therapy days to a new treatment, nonacog beta pegol.
  • Results suggest that overall spending on haemophilia B treatments may stay the same or decrease slightly (by up to 2.26%), contrasting with previous years' increasing costs, indicating the need for better pharmaceutical management.

Article Abstract

Objectives: to assess the variability in expenditure compared to 2022 assuming different rates of shifting of therapy days from current active ingredients used for the treatment of haemophilia B to nonacog beta pegolDesign: descriptive cross-sectional study.

Setting And Participants: consumption in the year 2022 (data source: Medicines Utilisation Monitoring Centre, Italian Medicines Agency) of all medicinal products available in Italy containing coagulation factor IX.

Main Outcomes Measures: for each active ingredient, the total number of therapy days and the variability in expenditure compared to 2022 were estimated on the basis of a switch of therapy days, between 5% and 20%, to nonacog beta pegol.

Results: on the basis of considered scenarios, the analysis shows that the total annual expenditure for clotting factors used in the treatment of haemophilia B could remain at most unchanged or reduced. Particularly, the extent of the reduction in spending could vary from 0.11% to 2.26%. This trend would be in contrast to the stable increase seen in recent years, particularly in 2022.

Conclusions: this predictive spending assessment may be useful in evaluating the economic impact from new treatment options, such as etranacogene dezaparvovec gene therapy already approved by the European Medicines Agency and the Food and Drug Administration, and to improve pharmaceutical governance.

Download full-text PDF

Source
http://dx.doi.org/10.19191/EP24.3.A718.059DOI Listing

Publication Analysis

Top Keywords

therapy days
12
variability expenditure
8
expenditure compared
8
compared 2022
8
treatment haemophilia
8
nonacog beta
8
medicines agency
8
[haemophilia therapy
4
therapy impact
4
impact reimbursability
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!